Unii-xab540T1CX | 26427-29-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: Unii-xab540T1CX
• 英文别名: [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 26427-29-2
• 化学式: C18H27N5O17P2
• 分子量: 647.4
• InChiKey: QSAWFXDVDTZAFB-SGOXFDQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.18
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  341
• 氢给体数：
  10
• 氢受体数：
  17

文献信息

• Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
  申请人：ABBOTT LABORATORIES

  公开号：US10813940B2

  公开（公告）日：2020-10-27

  Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

  所公开的营养组合物包括人乳低聚糖和核苷酸，可用于早产儿、足月儿、幼儿和儿童，以减少炎症和炎症性疾病的发病率。
• NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND NUCLEOTIDES AND USES THEREOF FOR TREATING AND/OR PREVENTING ENTERIC VIRAL INFECTION
  申请人：ABBOTT LABORATORIES

  公开号：US20180008623A1

  公开（公告）日：2018-01-11

  Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
• US9763970B2
  申请人：——

  公开号：US9763970B2

  公开（公告）日：2017-09-19
• [EN] ALLELE-SPECIFIC SILENCING OF TRANSFORMING GROWTH FACTOR BETA INDUCED GENE WITH R124H MUTATION USING SHORT INTERFERING RNA<br/>[FR] SILENÇAGE SPÉCIFIQUE D'ALLÈLE DE GÈNE INDUIT PAR LE FACTEUR DE CROISSANCE TRANSFORMANT BÊTA AVEC MUTATION R124H À L'AIDE D'ARN INTERFÉRANT COURT
  申请人：MOORE TARA

  公开号：WO2021117009A2

  公开（公告）日：2021-06-17

  The present disclosure relates to a ribonucleic acid (RNA) complex and methods of use thereof for preventing, ameliorating or treating symptoms associated with granular corneal dystrophy type 2 in a subject.